Scathing FTC PBM Report Allowed in Prime’s Price-fixing Case

In Featured, News by Ged Kenslea

Arbitrator denies motion to exclude critical new FTC Report on PBMs

 

LOS ANGELES, CA (August 2, 2024) AIDS Healthcare Foundation (AHF), the leading provider of health care to people living with HIV/AIDS around the world, won another legal battle in an American Arbitration Association arbitration against Prime Therapeutics LLC, one of the nation’s largest pharmacy-benefit managers (PBMs).

In a ruling on a pre-trial motion in limine in AHF v. Prime, Arbitrator Stuart M. Widman denied Prime’s request to exclude any reference to the Federal Trade Commission’s July 2024 interim report on PBMs from the upcoming arbitration. The damning interim report, “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies,” was issued last month.

“This FTC report treats PBMs fairly harshly, although AHF believes accurately and fairly, and it is good that Arbitrator Widman is willing to consider the report in his deliberations in this case,” said Jonathan M. Eisenberg, AHF’s Deputy General Counsel – Litigation and lead counsel for AHF in the arbitration. “The report has upended the PBM industry and may rouse Congress’ interest is considering PBM and drug-pricing reform.”

Background

As a PBM, Prime is a “middleman” in the distribution system for prescription drugs in the United States.[1]  Prime acts as an intermediary between health insurers and pharmacies, as well as pharmaceutical manufacturers.  Prime boasts of administering the pharmacy-benefits components of health insurance plans for about 38 million people in the United States.  Many of those people are patients of AHF pharmacies.

Since April 2020, Prime deliberately has been aligning its pharmacy reimbursement rates with those set by ESI.  The two PBMs no longer are competing on price to attract pharmacies into provider networks.  This scheme harms not only AHF and other pharmacies directly but also harms patients and the entire prescription drug pipeline.

  • July 31, 2024, Prime/AHF Arbitration: Ruling on Motion in Limine to Exclude FTC Interim Report  link
  • July 10, 2024, Prime/AHF arbitration summary adjudication ruling link

###

[1] Note: Prime is owned by a group of Blue Cross and/or Blue Shield health insurers.

Yes on 33: Kamala Harris Supports Rent Control
Prime Therapeutics Fails to Silence AHF in PBM Price-Fixing Arbitration